Wulfmeyer VC, et al. - Researchers performed this observational retrospective cohort analysis in a real-life autosomal dominant polycystic kidney disease (­ADPKD) cohort to compare different selection strategies for tolvaptan eligibility. Participants were 131 ADPKD patients aged 19–78 years. For each patient, they tested six different evaluation strategies. Findings revealed crucial differences between various decision algorithms for tolvaptan eligibility in ADPKD patients. The Scottish and the Japanese approach allowed the selection of the highest and the lowest patient number, respectively. They noted that few patients had positive recommendations by all 6 systems. Between the Scottish, U.K. and Canadian patient selection, they found strong congruency. Findings also revealed crucial differences between the ERA-EDTA and the US system because of varied emphases on parameters of kidney function vs kidney volume.